Concord Biotech's Q1 FY 2026-27 Quarterly Results

Result Summary

• Concord Biotech Ltd reported a 20.8% quarter-on-quarter (QoQ) decrease in its consolidated revenues for the quarter-ended Jun (Q1 FY 2026-27). On a year-on-year (YoY) basis, it witnessed a growth of 24.2%.
• Its expenses for the quarter were down by 14.9% QoQ and up 20.5% YoY.
• The net profit decreased 34.8% QoQ and increased 31.0% YoY.
• The earnings per share (EPS) of Concord Biotech Ltd stood at 5.52 during Q1 FY 2026-27.

Financial Statments for Q1 FY 2026-27

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Company Overview

Concord Biotech Ltd is a company known for its role in the biotechnology sector. The company is primarily engaged in the development, manufacturing, and marketing of biopharmaceutical ingredients and products. These products play a crucial role in healthcare and medical research, serving various therapeutic areas. Concord Biotech has been recognized for its commitment to innovation and quality in the field of biotechnology, which has contributed to its reputation and market presence. Recent developments in the company, if any, are not available from the given information. However, the financial data provided will give insights into the company's current performance and trends.

Revenue

In the first quarter of fiscal year 2027 (Q1FY27), Concord Biotech Ltd reported a total income of ₹270.31 crores. This represents a decrease from the previous quarter (Q4FY26), where the total income was ₹341.43 crores, indicating a quarter-over-quarter (QoQ) decline of 20.8%. However, when compared to the same quarter in the previous year (Q1FY26), where the total income was ₹217.67 crores, there is a year-over-year (YoY) increase of 24.2%. This data reflects the company's revenue dynamics over both short-term and long-term periods, highlighting variations in its income streams.

Profitability

For Q1FY27, Concord Biotech Ltd's profit before tax was ₹77.07 crores. This is a decrease from Q4FY26's profit before tax of ₹114.25 crores, representing a QoQ decline of 32.5%. Compared to Q1FY26, where the profit before tax was ₹57.24 crores, there is a YoY increase of 34.6%. The profit after tax for Q1FY27 stands at ₹57.70 crores, down from ₹88.47 crores in Q4FY26, showing a QoQ decrease of 34.8%. Year-over-year, this figure represents an increase of 31.0% from Q1FY26's profit after tax of ₹44.06 crores. These figures reflect the company's profitability trends over different periods.

Operating Metrics

Concord Biotech Ltd's total expenses for Q1FY27 were ₹193.25 crores, decreasing from ₹227.17 crores in Q4FY26, which translates to a QoQ reduction of 14.9%. When compared to Q1FY26, where expenses were ₹160.43 crores, there is a YoY increase of 20.5%. The tax expense for Q1FY27 was ₹20.65 crores, a decline from Q4FY26's ₹25.61 crores, marking a 19.4% decrease QoQ. Year-over-year, this represents a 40.8% increase from ₹14.67 crores in Q1FY26. Earnings per share (EPS) for Q1FY27 were ₹5.52, which decreased from Q4FY26's ₹8.46, showing a QoQ decline of 34.8%. Compared to Q1FY26, where the EPS was ₹4.21, there is a YoY increase of 31.1%. These metrics provide insights into the company's operational efficiency and shareholder value generation over the analyzed periods.